ClinicalTrials.gg
CompletedNCT06901505Updated Nov 16, 2026

To Evaluate the Efficacy of Three Times Weekly (TIW) Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis

A Phase 3 interventional study of Erythropoiesis-Stimulating Agent (ESA) and Vadadustat in Anemia of Chronic Kidney Disease, sponsored by Akebia Therapeutics. Completed at 18 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Akebia Therapeutics · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
353
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies testing vadadustat in Renal Insufficiency, Chronic — none open to participants now, none under way, none of them phase 3. vadadustat · Renal Insufficiency, Chronic.

Enrollment
6th of 18
353 · median 94
Started
2025
with 2 others
Phase 3
8 of 18
none open now
Registered
18th of 18
by date
Lead sponsor
18 of 18
Akebia Therapeutics

Among the 18 studies testing vadadustat in Renal Insufficiency, Chronic, this one is the 6th largest by enrollment, is one of 3 that started in 2025, is one of 8 in phase 3, and was the 18th registered.

Renal Insufficiency, Chronic

3,096 studies on the registry are indexed under Renal Insufficiency, Chronic; 701 are open to participants now.

Browse Renal Insufficiency, Chronic studies →

Open to participants now

None of the 18 studies testing vadadustat in Renal Insufficiency, Chronic is open now. The open studies under Renal Insufficiency, Chronic, anywhere →

About vadadustat

vadadustat: first FDA approval 2024 (VAFSEO), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 434 Renal Insufficiency, Chronic studies recruiting now, 244 (56%) set no upper age limit and 110 (25%) stop at 75 or younger; 44 take children under 18; 80 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 18 studies testing vadadustat in Renal Insufficiency, Chronic as a file.
02

Study summary

This is a multi-center, randomized (1:1), open-label, active-controlled, pragmatic study of the efficacy of vadadustat administered three times a week compared to standard of care erythropoiesis-stimulating agent for the treatment of anemia in in-center hemodialysis participants with end-stage kidney disease (ESKD). A subset of sites will participate in a red blood cell (RBC) sub-study where changes in the phenotype of RBCs in response to vadadustat treatment relative to methoxy polyethylene glycol-epoetin beta treatment in DD-CKD participants with anemia will be assessed. A separate informed consent form (ICF) will be signed by these participants who opt to be in the RBC sub-study. Of the 350 participants in the main study, approximately 28 participants will also be enrolled into the RBC sub-study. The total duration of the study is approximately 35 Weeks including screening and follow-up.

03

Conditions studied

  • Anemia of Chronic Kidney Disease

Keywords

  • Chronic Kidney Disease
  • Hemodialysis
  • Erythropoiesis-Stimulating Agent
  • Open-label
  • Vadadustat
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult participants ≥18 years of age.
  • Receiving outpatient in-center hemodialysis for ESKD at least three times a week.
  • Currently prescribed or meets criteria for ESA based on approved facility policy.
  • > 8 grams per deciliter (g/dl).
  • Serum ferritin ≥100 nanograms per milliliter (ng/mL) and transferrin saturation (TSAT) ≥20%.
  • Understands the procedures and requirements of the study and provides written and authorization for protected health information disclosure.
  • For selected sites, individuals who opt to participate in the RBC sub-study must meet the following inclusion criteria:
  • Currently prescribed or will be prescribed methoxy polyethylene glycol-epoetin beta.
  • Hb \<11.5 g/dL

Exclusion criteria

Exclusion Criteria:

  • to receive vadadustat per United States prescribing information (USPI) as determined by the treating health care provider.
  • Concomitant use of any hypoxia-inducible factor prolyl hydroxylase inhibitor(HIF-PHI).
  • Known cirrhosis or active, acute liver disease.
  • Unable to comply with study requirements or compliance with attending dialysis treatments as prescribed, or in the opinion of the treating physician or Investigator, not clinically stable to participate in the study.
  • Pregnant at the time of consent (per participant self-report).
  • Any other reason, which in the opinion of the Investigator, would make the participants unsuitable for participation in the study.
  • For selected sites, individuals who opt to participate in the RBC sub-study must also not meet the following exclusion criteria:
  • History of, or currently diagnosed with, any hematological disease, such as sickle cell disease, thalassemia, hemochromatosis, Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency, myelodysplastic syndromes, or any other blood disorder that could interfere with the study outcomes.
  • Participants will receive a blood transfusion within 3 months prior to the initiation of the study.
  • History of or currently diagnosed with chronic lung disease
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
353 participants (actual)

Study arms

  • Experimental
    Vadadustat

    Study drug will be administered three times a week.

    Drug: Vadadustat

  • Active comparator
    Erythropoiesis-Stimulating Agent (ESA)

    Dose adjustments will be determined by hemoglobin (Hb) change and current dose of ESA, per ESA dosing protocol

    Drug: Erythropoiesis-Stimulating Agent (ESA)

Interventions

06

What researchers measure

Primary outcomes

  1. Change in hemoglobin (Hb)

    Time frame: Baseline and the mean of Week 20 to 24

Secondary outcomes

  1. Number of participants reporting treatment-emergent serious adverse events (TESAEs)

    Time frame: Up to 29 Weeks

  2. Proportion of participants with mean Hb levels within target range

    Time frame: Week 16 to Week 24

  3. Proportion of participants receiving RBC transfusions

    Time frame: Up to 29 Weeks

07

Study locations

18 sites
  • DaVita Research Site
    Montgomery, Alabama 36117-7306, United States
  • DaVita Research Site
    Hartford, Connecticut 06112-1260, United States
  • DaVita Research Site
    Middlebury, Connecticut 06705-3893, United States
  • DaVita Research Site
    Columbus, Georgia 31904-3604, United States
  • DaVita Research Site #1
    Minneapolis, Minnesota 55435-1807, United States
  • DaVita Research Site
    Minneapolis, Minnesota 55435-1807, United States
  • DaVita Research Site
    Henderson, Nevada 89052-5548, United States
  • DaVita Research Site
    Las Vegas, Nevada 89128-0804, United States
  • DaVita Research Site #1
    El Paso, Texas 79835-2200, United States
  • DaVita Research Site
    El Paso, Texas 79835-2200, United States
  • DaVita Research Site #1
    Houston, Texas 77054-3836, United States
  • DaVita Research Site
    Houston, Texas 77054-3836, United States
  • DaVita Research Site #1
    San Antonio, Texas 78258-4800, United States
  • DaVita Research Site #2
    San Antonio, Texas 78258-4800, United States
  • DaVita Research Site
    San Antonio, Texas 78258-4800, United States
  • DaVita Research Site
    The Woodlands, Texas 77384-3024, United States
  • DaVita Research Site #1
    Norfolk, Virginia 23502-3235, United States
  • DaVita Research Site
    Norfolk, Virginia 23502-3235, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2025 to primary completion in Aug 2026, 12 months.

Of 104 industry-sponsored phase 3 interventional studies under Renal Insufficiency, Chronic, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 49. This study's 12 months is below that.

Counting every sponsor, half of 145 studies reached it within 32 months; a quarter within 19 and three quarters within 54.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 27, 2025
First posted
Mar 30, 2025
StartActual
Jul 24, 2025
Primary completionActual
Aug 12, 2026
CompletionActual
Aug 12, 2026
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06901505
Responsible party
Sponsor
First posted
Mar 30, 2025
Start date
Jul 24, 2025
Primary completion
Aug 12, 2026
Completion
Aug 12, 2026
Last update
Nov 16, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vadadustat

Start the discussion